Singapore Chronic Cough Therapeutics Market was valued at $8 Mn in 2022 and is estimated to reach $15 Mn in 2030, exhibiting a CAGR of 8.7% during the forecast period. The predominant factor driving the growth of the chronic cough therapeutics market is the prevalent occurrence of persistent coughing associated with chronic respiratory infections. Leading entities in this sector currently include Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Hikma Pharmaceuticals, and Abbott Laboratories.
Singapore Chronic Cough Therapeutics Market was valued at $8 Mn in 2022 and is estimated to reach $15 Mn in 2030, exhibiting a CAGR of 8.7% during the forecast period.
A chronic cough is characterized by its persistence for more than eight weeks, setting it apart from short-term coughs associated with temporary conditions. In contrast to transient coughs typically linked to infections, a chronic cough may indicate a prolonged underlying health issue. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications are common culprits behind chronic cough. It is crucial to identify and address the underlying cause through a comprehensive medical evaluation for effective management. Chronic cough can significantly impact the quality of life, often necessitating a holistic, multidisciplinary approach that involves healthcare professionals like pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.
In Singapore, chronic cough emerges as a prevalent reason leading to referrals to respiratory physicians, constituting the most frequent presentation in approximately 25% of general practitioner and polyclinic visits. Among the non-smoking adult population, the prevalence of chronic cough ranges from 14-23%. Significant contributors to chronic cough in this context include postnasal drip syndrome, postinfectious cough, gastro-oesophageal reflux disease, and cough variant asthma. Less common triggers involve the use of angiotensin-converting enzyme inhibitors, smoker's cough, and non-asthmatic eosinophilic bronchitis. While chronic cough is generally not life-threatening, it carries the potential for rare but serious complications, including pneumothorax, syncope, and cardiac arrhythmias.
The National University of Singapore (NUS) and GlaxoSmithKline (GSK) have joined forces in a research collaboration for a $4.7 Mn project. This initiative aims to explore the role of the microbiome in respiratory diseases, with a specific focus on chronic cough.
The Agency for Science, Technology, and Research (A*STAR) directs its efforts toward the advancement of new technologies dedicated to the diagnosis and treatment of respiratory diseases. Their research encompasses potential applications for addressing chronic cough, reflecting a commitment to innovative approaches in the field.
Market Growth Drivers
Aging population: As of 2022, 16.6% of Singapore's resident population comprises individuals aged 65 years and above. Projections indicate that this percentage is anticipated to increase to 23.8% by the year 2030 and further escalate to 36% by 2050. The aging demographic in Singapore is particularly vulnerable to chronic cough, primarily attributed to underlying health conditions such as asthma, chronic obstructive pulmonary disease (COPD), and gastroesophageal reflux disease (GERD). This ongoing demographic shift toward an older population is foreseen to persist, contributing significantly to the continued growth of the market for chronic cough therapeutics.
Changing Lifestyles and Environmental Factors: Evolving lifestyles, urbanization, and exposure to environmental pollutants contribute to the escalation of respiratory disorders, necessitating a higher demand for chronic cough therapeutics.
Awareness and Diagnosis Improvement: Heightened awareness regarding chronic cough symptoms and advancements in diagnostic capabilities lead to more accurate and timely identification of the condition, fostering the demand for therapeutic interventions.
Market Restraints
Cultural Perceptions and Traditional Remedies: In Singapore, people might turn to homeopathic or traditional remedies influenced by cultural attitudes and preferences, impacting their perception of persistent coughs. Encouraging the acceptance of modern treatment alternatives among both healthcare professionals and patients could present a challenge for the industry.
Side Effects and Safety Concerns: Potential side effects or safety concerns associated with certain chronic cough therapeutics may raise apprehensions among both healthcare providers and patients. This could lead to a more cautious adoption of these treatments, impacting market growth.
Reliance on Symptomatic Treatment: The predominant use of symptomatic treatment approaches for chronic cough, rather than addressing the underlying causes, may limit the effectiveness of available therapeutics. This reliance on managing symptoms rather than curing the root cause can be a constraint in achieving long-term success.
The Health Sciences Authority (HSA), as the primary regulatory body ensuring the safety and quality of health products, plays a crucial role in overseeing Singapore's regulatory landscape and healthcare regulations governing therapeutic pharmaceuticals. The Ministry of Health (MOH), in collaboration with HSA, is instrumental in establishing healthcare standards and policies. The Pharmacy Practice Act provides guidelines for drug distribution, overseeing both pharmacy practices and the sale of therapeutic products. The National Medicines Policy (NMP), integrated into the broader healthcare policy framework, guides the distribution and control of pharmaceuticals. Additionally, payment regulations may be influenced by health insurance coverage, such as the Central Provident Fund (CPF) and various health insurance plans, potentially impacting patients' access to specific treatment medications.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Class
By Route of Administration
By End-Users
By Distribution Channel
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.